Acadia Pharma (ACAD) Tops Q4 EPS by 146c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.09 +2.17%
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $1.60, $1.46 better than the analyst estimate of $0.14. Revenue for the quarter came in at $284 million versus the consensus estimate of $293.78 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.2 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Meta pauses an AI training program that tracks employees' keystrokes after a companywide leak - Insider
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
